Solstein Capital’s Edwards Lifesciences EW Stock Holding History

Solstein Capital’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.96K	Hold	77	–	–	﹤0.01%	352
2026 Q1	$6.17K	Hold	77	–	–	﹤0.01%	359
2025 Q4	$6.56K	Hold	77	–	–	﹤0.01%	360
2025 Q3	$5.99K	Hold	77	–	–	﹤0.01%	367
2025 Q2	$6.02K	Hold	77	–	–	﹤0.01%	378
2025 Q1	$5.58K	Hold	77	–	–	﹤0.01%	269
2024 Q4	$5.7K	Hold	77	–	–	﹤0.01%	266
2024 Q3	$5.08K	Hold	77	–	–	﹤0.01%	276
2024 Q2	$7.11K	Hold	77	–	–	﹤0.01%	255
2024 Q1	$7.36K	Hold	77	–	–	0.01%	253
2023 Q4	$5.87K	Hold	77	–	–	﹤0.01%	258
2023 Q3	$5.33K	Hold	77	–	–	﹤0.01%	253
2023 Q2	$7.26K	Hold	77	–	–	0.01%	242
2023 Q1	$6.37K	Hold	77	–	–	0.01%	219
2022 Q4	$5.75K	Hold	77	–	–	﹤0.01%	234
2022 Q3	$6K	Hold	77	–	–	0.01%	254
2022 Q2	$7K	Hold	77	–	–	0.01%	277
2022 Q1	$9K	Hold	77	–	–	0.01%	299
2021 Q4	$10K	Hold	77	–	–	0.01%	321
2021 Q3	$9K	Hold	77	–	–	0.01%	363
2021 Q2	$8K	Hold	77	–	–	0.01%	347
2021 Q1	$6K	Buy	+77	New	+$6.51K	0.01%	330
2020 Q2	–	Sell	-21	Closed	-$1K	–	245
2020 Q1	$1K	Sell	21 -177	-89%	-$12.8K	﹤0.01%	250
2019 Q4	$15K	Buy	+198	New	+$15.5K	0.03%	224

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Solstein Capital's EW Position: Q2 2026 in Review

Solstein Capital held its Edwards Lifesciences (EW) position steady in Q2 2026 at 77 shares worth $6.96K. The position accounts for ﹤0.01% of the portfolio, ranked #352.

Solstein Capital first reported a position in EW in Q4 2019 and has held it in 24 quarters since. The position peaked at $15K in Q4 2019. 1,338 funds tracked by Wall St. Rank hold EW as of Q2 2026.

Solstein Capital held 77 shares of Edwards Lifesciences worth $6.96K as of Q2 2026.
Solstein Capital left its Edwards Lifesciences share count unchanged in Q2 2026.
Edwards Lifesciences made up ﹤0.01% of Solstein Capital's portfolio in Q2 2026, its #352 holding.
Solstein Capital first reported a position in Edwards Lifesciences in Q4 2019 and has held it in 24 quarters since.
Solstein Capital's Edwards Lifesciences position peaked at $15K in Q4 2019.
1,338 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Solstein Capital's 13F filing for Q2 2026, filed 13 Aug 2026.